Suryaa Business Desk: Biotechnology company Moderna has announced a revision to its annual revenue forecast for the current fiscal year due to an unexpected surge in international demand for COVID-19 vaccines. The company reported that increased sales in foreign markets and the expedited distribution of vaccines tailored to new variants have positively impacted its financial results.
Management stated that the total revenue projection for the end of the year has been significantly increased compared to previous estimates. The company is currently focusing on streamlining research and development expenditures and prioritizing high-profit markets to stabilize profit margins.
Despite the decline in the intensity of the pandemic, consistent government vaccine purchases and ongoing public health awareness continue to support vaccine manufacturers. Investors are also noting the progress of Moderna’s new vaccines for respiratory syncytial virus (RSV) as a potential foundation for future growth. Following these developments, Moderna shares saw an increase on Wall Street as the company continues to adjust production to meet international demand.
